More Publications

Original papers first author

 

K. H. Link, M. Roitman, Th. Müller, F. Strobel, E. Bungert
Notfälle in der Geriatrie aus viszeralchirurgischer Sicht.
Neuro-Geriatrie 2, 71-72, 2013

K. H. Link,
Therapie von Tumoren der Bauchspeicheldrüse bei VHL Betroffenen.
VHL Rundbrief, 13, 4-7, 2012

K. H. Link, H. Hauser, M. Mann, P. M. Schlag.
Kolonkarzinom. Die Sicht der Chirurgie.
Wiener Klinisches Magazin 3, 18-24, Wiener Klinische Wochenschrift 11-12, 2011

K. H. Link, M. Kornmann, R. Bittner, F. Köckerling, R. Arbogast, I. Gastinger, W. Heitland, D. Henne-Bruns, H. Lang, H. Lippert, M. Mann, H. J. Meyer, M.-J. Polonius, S. Post, R. Raab, T. Schiedeck, Schumpelick
Qualitätsanforderungen zur Behandlung des Kolon- und Rektumkarzinoms – Aus chirurgischer Sicht
Chirurg 81, 222-230, 2010

K. H. Link, M. Kornmann, R. Bittner
Multimodale Therapie von Kolon- und Rektumkarzinomen: Qualitätsparameter Gastrointestinal Medicine and Surgery
Viszeralmedizin 2009; 25: 105-117

K. H. Link, M. Roitman
How to treat Peritoneal Metastases or Primary Tumors
Proceedings/Abstract Book, 20th ICACT, MTP 16, 166-171, 2009
www.icact.com

K. H. Link, M. Roitman, M. Mann, B. Schneider, Th. Weber
New Management in the Treatment of Colorectal Cancer
Proceedings/Abstract Book, 19th ICACT, EL -9, 95-99, 2008

K. H. Link, M. Kornmann, M. Mann, L. Staib
Quality Control in Interdisciplinary Colon- and Rectal Cancer Treatment: Case Load or more?
Proceedings/ Abstract Book 18th
International Congress on Anti Cancer Treatment (ICACT) 2007

K. H. Link, P. M. Schlag
Exzessive Palliativchirurgie
Chirurgische Gastroenterologie, 23, 330-331, 2007

K. H. Link, T. Weber
Radikale Chirurgie bei primär metastasierten kolorektalen Karzinomen
Chirurgische Gastroenterologie, 23, 360-366, 2007

K. H. Link
Diagnose und chirurgische Therapie von Bauchspeicheldrüsentumoren
VHL-Rundbrief, Heft 3, Jahrgang 8, 5-9, 2007

K. H. Link, L. Staib, W. Baumann, M. Redenbacher, S. Sander, D. Henne-Bruns, M. Kornmann
Modulation of adjuvant 5-FU treatment by folinic acid and interferon-alpha in colon and rectal cancer: Comparison of two phase-III trials including 1652 patients
European Journal of Surgical Oncology (EJSO), Volume 32, Suppl.I, 585-592, 2006

K. H. Link, T.A. Sagban, M. Mann
Surgery and Multimodal Therapy in Rectal Cancer
Proceedings/Abstract Book 17th International Congress on Anti Cancer Treatment (ICACT) 98-110, 2006

K. H. Link, M. Kornmann, L. Staib, M. Redenbacher, M. Kron , H.G. Beger
Increase of Survival Benefit in Advanced Resectable Colon Cancer by Extent of Adjuvant Treatment: Results of a Randomized Trial Comparing Modulation of 5-FU + Levamisole with Folinic Acid or with Interferon-?
Annals of Surgery, 2005, Volume 242, Number 2, 178-187

K. H. Link, T.A. Sagban, Z.L. Ji
Surgery and Multimodal Therapy in Colon and in Rectal cancer
Journal of Clinical Medicine in Practice, 9, 2005, 9-27

K. H. Link, T.A. Sagban, M. Moerschel, K. Tischbirek, M. Holtappels, V. Apell, K. Zayed, M. Kornmann, L. Staib
Colon cancer: survival after curative surgery
Langenbeck´s Archives of Surgery, 390, 83-93, 2005

K. H. Link, M. Mörschel, TA Sagban, V. Apell, M. Holtappels, K. Tischbirek
Chirurgie und multimodale Therapie des Kolonkarzinoms: Evidenzbasis
Chirurgische Gastroenterologie, 20 (1), 39-54, 2004

K. H. Link, M. Roitman, M. Holtappels, I. Runnebaum, H. Urbanzyk, G. Leder, L. Staib
Intraperitoneal chemotherapy with mitoxantrone in malignant ascites
Surg Oncol Clin N Am, 12(3), 865-872, 2003

K. H. Link
Laudatio zur Emeritierung von Herrn Prof. Beger, Univ Ulm Intern, 349, II/01, 2001

K. H. Link, E. Sunelaitis, M. Kornmann, M. Schatz, F. Gansauge, G. Leder, A. Formentini, L. Staib, Pillasch, H-G. Beger
Regional Chemotherapy of Nonresectabele Colorectal Liver Metastases with Mitoxanrone, 5-Fluorouracil, Folinic Acid, and Mitomycin C May Prolong Survival
Cancer, 92, 2746-53, 2001

K. H. Link, G. Leder, A. Formentini, H.G. Beger
Impact of celiac arteryinfusion chemotherapy (CAI) or CAI+Radiotherapy on tumor biology and survival in resected and locally advanced nonresectable pancreatic cancer
Anticancer Research 21, 1598-1599, 2001

K. H. Link
Wandel der Therapie bei resektablem Rektumkarzinom
Der Internist, 42:910-912, 2001

K. H. Link, L. Staib, M. Kornmann, A. Formentini, M. Schatz, P. Suhr, P. Messer, E. Röttinger, H.G. Beger
Surgery, Radio- and Chemotherapy for Multimodal Treatment of Rectal Cancer
Swiss Surgery 7,256-274, 2001

K. H. Link, G. Leder, A. Formentini, H.G. Beger
Impact of celiac arteryinfusion chemotherapy (CAI) or CAI+Radiotherapy on tumor biology and survival in resected and locally advanced nonresectable pancreatic cancer
Anticancer Research 21, 1598-1599, 2001

K. H. Link, M. Kornmann, U. Butzer, G. Leder, E. Sunelaitis, J. Pillasch, D. Salonga, K.D. Danenberg, P.V. Danenberg, H-G. Beger
Thymidylate Sythase Quantitation an In Vitro Chemosensitivity Testing Predicts Responses and Survival of Patients with Isolated Nonresectable Liver Tumors Receiving Hepatic Arterial Infusion Chemotherapy
Cancer, 89, Nr. 2, 288-296, 2000

K. H. Link, J. Pillasch, A. Formentini, E. Sunelaitis, G. Leder, F. Safi, M. Kornmann, H.G. Beger
Downstaging by regional chemotherapy of nonresectable isolated colorectal liver metastases.
European Journal of Surgical Oncology 25 (1999), 381-388

K. H. Link, A. Formentini, G. Leder, G. Fortnagel, N. Warszawski, E. Papachristou, M.B. Lutz, M. H. Schoenberg, H.G. Beger
Systemische und regionale Chemotherapie, Strahlentherapie und Kombinationsbehandlungen beim Pankreaskarzinom.
Verdauungskrankheiten 16 (1998) 189-198

K. H. Link, A. Formentini, G. Leder, G. Fortnagel, N. Sartori, M. Schatz, H.H. Beger
Resection and Radiochemotherapy of Pancreatic Cancer – The Future?
Langenbeck’s Archives of Surgery 383 (1998) 134-144

K. H. Link, L. Staib, M. Schatz, P. Suhr, E. Röttinger, H.G. Beger
Rectal Cancer: Adjuvant radiochemotherapy – what is the patients benefit?
Langenbeck’s Archives of Surgery 383 (1998) 416-426

K. H. Link, L. Staib, M. Schatz, P. Suhr, E. Röttinger, H.G. Beger
Multimodal therapy in rectal cancer.
Japanese Journal of Cancer and Chemotherapy 25 (14) (1998) 2167-2192

K. H. Link, G. Leder, J. Pillasch, U. Butzer, L. Staib, M. Kornmann, U. Brückner, H. G. Beger
In vitro concentration response studies  and in vitro phase II tests as the experimental basis for regional chemotherapeutic protocols.
Seminars in Surgical Oncology 14 (1998) 189-201

K. H. Link, L. Staib, H. Bernhart, E.D. Kreuser, P. Suhr, E. Röttinger, H.G. Beger
Acceptance and toxicity of postoperative adjuvant therapy in colon and rectal cancers. Interim Report on the Trials FOGT 1 and FOGT 2 of the German Forschungsgruppe Onkologie
Gastrointestinaler Tumoren (FOGT).
Onkologie 20 (1997) 235-238

K. H. Link, F. Gansauge, J. Görich, G. H. Leder, N. Rilinger, H.G. Beger
Palliative and adjuvant regional chemotherapy in pancreatic cancer.
Eur.J.Surg.Oncol.23 (1997) 409-414

K. H. Link, F. Gansauge, N. Rilinger, H.G. Beger
Celiac Artery Adjuvant Chemotherapy.
Int. J. Pancreatol 21 (1997) 65-69

K. H. Link, F. Gansauge, J. Pillasch, H.G. Beger
Multimodal Therapies in Ductal Pancreatic Cancer.
Int. J. Pancreatol. 21 (1997) 71-83

K. H. Link, A. Formentini, F. Gansauge, E. Papachristou, H.G. Beger
Regional celiac artery infusion as adjuvant treatment after pancreatic cancer resection.
Digestion 58 (1997), 529-532

K. H. Link, F. Gansauge, M. H. Schoenberg, L. Staib, A. Formentini G. Fortnagel, Warszawski, M.B. Lutz, Th. Gress, H. G. Beger
Palliative, adjuvante Therapieoptionen beim Pankreaskarzinom unter Berücksichtigung der regionalen Chemotherapiemöglichkeiten.
Acta Chir. Austriaca 29 (1997) 281-289

K. H. Link, L. Staib, E.-D. Kreuser, H.G. Beger
Adjuvant Treatment of Colon and Rectal Cancer: Impact of Chemotherapy, Radiotherapy, and Immunotherapy on Routine Postsurgical Patient Management.
Recent Results Cancer Research 142 (1996) 311-352

K. H. Link, M. Kornmann, G. Leder, U. Butzer, J. Pillasch, L. Staib, F. Gansauge, H. G.Beger
Regional Chemotherapy Directed by Individual Chemosensitivity Testing in Vitro: A Prospective Decision-aiding Trial.
Clinical Cancer Research 3 (1996) 1469-1474

K. H. Link, G. Hepp, L. Staib, U. Butzer, W. Böhm, H.G. Beger
Intraperitoneal regional chemotherapy with mitoxantrone.
Cancer Treatment and Research 81 (1996) 31-40

K. H. Link, U. Butzer, J. Pillasch, G. Hepp, H.G. Beger
In vitro pharmalogic rationale for intraperitoneal regional chemotherapy.
Cancer Treatment and Research 82 (1996) 101-114

K. H. Link, M. Kornmann, H.-J. Lenz, U. Butzer, J. Pillasch, F. Safi, F. Gansauge, K. D. Danenberg, P. V. Danenberg, H. G. Beger
Response prediction in hepatic artery infusion with fluoropyrimidines using cell culture and thymidylate synthase quantitation.
Reg. Cancer Treat. 8 (1995) 115-121

K. H. Link, G. Hepp, U. Butzer, L. Staib, R. Kunz, J. Pillasch, F. Gansauge, Ch. Schaller, H. G. Beger
Rationales for Intraperitoneal Chemotherapy: Chemosensitivity Testing and Pharmacokinetic Considerations – Clinical Experience with Intraperitoneal Chemotherapy.
Acta Chir. Austriaca 27 (1995) 95-100

K.H.Link
Chemosensitivitätsuntersuchungen zur Optimierung der Regionalen Chemotherapie solider Tumoren. Grundlagen und Klinische Applikation.
Habilitationsschrift, Fakultät für Klinische  Medizin, Universität Ulm (1994)

K. H. Link, F. Gansauge, J. Pillasch, N. Rilinger, M. Büchler, H.G. Beger
Regional Treatment of Advanced Nonresectable and of Resected Pancreatic Cancer via Celiac Axis Infusion. (First Results of a Single Institution Study)
Dig Surg 11 (1994) 414-419

K. H. Link, K.R. Aigner, J. Pillasch, J. Ullrich, F. Gansauge and D.H. Kern
Individual Chemosensitivity Testing for Regional Chemotherapy in a Prospective Correlative and a Prospective Decision Aiding Test.
Reg Cancer Treat 3 (1993) 113-120

K. H. Link, E.D. Kreuser, F. Safi, J. Ullrich, A. Schalhorn, E. Schmoll, H.G. Beger
Die intraarterielle Chemotherapie mit 5-FU und Folinsäure (FA, Rescuvolin) im Therapiekonzept bei nicht resektablen kolorektalen Lebermetastasen. Ein Vergleich von 5-FU/FA i.a. vs. 5-FU/FA i.v. vs. 5-FUDR i.a. oder 5-FUDR i.a.+i.v.
Tumor Diagnostik und Therapie 14 (1993) 224-231

K. H. Link, H.G. Beger
Was ist gesichert in der Chemo- und Immuntherapie solider Tumoren. Standardprotokolle, Studien und neue Entwicklungen.
Chirurg 63 (1992) 401-409

K. H. Link, M. Büchler
Levamisol und Fluorouracil zur adjuvanten Therapie des resezierten Kolonkarzinoms?
Arzneimitteltherapie 4 (1992) 101-103

K. H. Link, G. Hepp, L. Staib, R. Kunz, U. Butzer, W. Böhm, H.G. Beger
Intraperitoneale regionale Chemotherapie (IPRC) mit Mitoxantron. Grundlagen und Klinik.
Aktuelle Onkologie 66 (1992) 18-32

K. H. Link
In vitro Interaktion von Mezlocillin mit 5-Fluorouracil und mit Mitomycin C.
Arzneimittelforschung/Drug Research 39 (II), 11 (1989) 1403-1405

K. H. Link, L. Staib, H.G. Beger
Influence of exposure concentration and exposure time (cxt) on toxicity of cytostatic drugs to HT29 human colorectal carcinoma cells. Characterization of drugs for (regional) chemotherapy.
Regional Cancer Treatment 2 (1989) 189-197

K. H. Link, K.R. Aigner, D. Kessler
In vitro chemosensitivity profiles of human malignancies for high dose regional chemotherapy.
Contributions to Oncology 29 (1988) 28-42

K. H. Link, K.R. Aigner, K. Peschau, M. Warthona, K. Schwemmle, P.V. Danenberg
Concentration and time dependence of the toxicity of fluorinated pyrimidines to HT29 colorectal carcinoma cells.
Cancer Chemotherapy and Pharmacology 22 (1988) 58-62

K. H. Link, K.R. Aigner, W. Kuehn, K. Schwemmle, D.H. Kern
Prospective correlative chemosensitivity testing in high-dose intraarterial chemotherapy for liver metastases.
Cancer Research 46 (1986) 4837-4840

K. H. Link, K.R. Aigner, W. Kühn, N. Roetering, K. Schwemmle
Chemosensitivitätsbestimmung in vitro bei regionaler Chemotherapie von Lebertumoren.
Tumor Diagnostik & Therapie 6 (1985) 238-243

K. H. Link, K.R. Aigner, W. Kühn, N. Rötering
Zytostatikasensitivitätstestung perioperativ und im Tumorzell-Kolonien-Test (TKT) in vitro bei hochdosierter intraarterieller Chemotherapie (HDIAC) von Lebermetastasen.
Beitr.Onkol. 21 (1985) 181-200

K. H. Link, Ch. Heidelberger, J. Landolph
Induction of Quabain-resistant mutants by chemical carcinogens in rat prostate epithelial cells. Environmental Mutagenesis  5 (1983) 33-48

 

Original papers coauthor

Marko M. Kornmann, Karl-Heinrich Link & Andrea Formentini.
Differences in colon and rectal cancer chemosensitivity.
Colorect.Cancer 3(1), 1-13, 2014

Thomas Thomaidis, Annett Maderer, Andrea Formentini, Susanne Bauer, Mario Trautmann, Michael Schwarz, Wiebke Neumann, Jens Kittner, Arno Schad, Karl-Heinrich Link, Johannes Rey, Arndt Weinmann, Arthur Hoffman, Peter Galle, Marko M. Kornmann and Markus Moehler.
Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial.
Journal of Experimental & Clinical Cancer Research, 33:83 (02 Oct 2014)
http://www.jeccr.com/content/33/1/83

Marko M. Kornmann, Ludger Staib, Thomas Wiegel, Martina Kron, Doris Henne-Bruns, Karl-Heinrich Link, Andrea Formentini for the Study Group Ocology of Gastrointenstinal Tumors (FOGT).
Long Term Results of 2 Adjuvant Trials Reveal Differences in Chemosensitivity and the Pattern of Metastases between Colon Cancer and Rectal Cancer.
Clinical Colorectal Cancer 12 (1), 54-61, 2013

Th. Weber, M. Roitman, K. K. H. Link.
Peritonealkarzinose kolorektalen Ursprungs. Ergebnisse der Cytoreduktiven Chirurgie mit Peritonektomie und Hyperthermer Intraoperativer Chemotherapie.
Chirurg 84, 130-139, 2013  E-pup (ahead of print 14.12.2012) DOI 10.1007/s00104-012-2419-2

M. Kornmann, H. Hebart, K. Danenberg, R. Goeb, L. Staib, M. Kron, D. Henne-Bruns, P. Danenberg, K-H- Link.
Response prediction in metastasized colorectal cancer using intratumoral thymidylate synthase Results of a randomized multicentre trial
Eur J Cancer 48 (10) 1443-51, 2012 (Epub 2011 Nov29)

Formentini, P. Braun, H. Fricke, K-K. H. Link, D. Henne-Bruns, M. Kornmann.
Expression of interleukin-4 and interleukin-13 and their receptors in colorectal cancer
Int.J.Colorectal Dis.2012 Mar 24 [Epub ahead of print]

Th. Weber, M. Roitman, K. K. H. Link.
Current Status of Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Patients With Peritoneal Carcinomatosis From Colorectal Cancer.
Clinical Colorectal Cancer 11 (3), 167-76, 2012

v. Knebel-Doeberitz et al. (u.a. K. H. Link, M. Kornmann)
Br.J.Cancer 2012

M. Kornmann, L. Staib, T. Wiegel, E.-D. Kreuser, M. Kron, W. Baumann, D. Henne-Bruns and K. H. Link.
Adjuvant chemoradiotherapy of advanced resectable rectal cancer:
results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with
interferon-a.
British Journal of Cancer 103, 1163-1172, 2010

W.Schmiegel et al.
S3 Guidelines of Colorectal Carcinoma. Results of an Evidence-Based Consensus Conference on Colon- and Rectal Cancer.
February 6/7, 2004 and June 8/9 2007 (for the Topics IV, VI and VII). (K. H. Link member of  Work Group VI)
Z Gastroenterolo 48, 65-136, 2010

Thomas Weber, Karl-Heinrich Link.
Kolon: Pro Chirurgie.  Hauptthema “Submukosakarzinome”.
Viszeralmedizin 25, 40-45, 2009

Hohenberger, W, K. H. Link, J. Spatz und M. Anthuber, U. Widmaier und M. H. Schoenberg.
Stellenwert der laparoskopischen operativen Behandlung von Rektumkarzinomen.
Chirurgische Praxis 70, 3-9, 2009

M. Kornmann, A. Formentini, C. Ette, D. Henne-Bruns, M. Kron, S. Sander, W. Baumann, E.-D. Kreuser, L. Staib, K. H. Link,
Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment .
European Journal of Surgical Oncology (EJSO), Volume 34, 1316-1321, 2008

M. Kornmann, L. Staub, S. Sander, D. Henne-Bruns, K. H. Link.
Prognostic factors influencing the outcome of 1652 patients with colon or rectal cancer receiving adjuvant 5-FU-based.
European Journal of Surgical Oncology (EJSO), Volume 32, Suppl.I, 58-59, 2006

G. Beger, M. D. ; Bettina Rau, M. D.; Ph D., Frank Gansauge, M. D., Bertram Poch M. D., K. H. Link.
Treatment of pancreatic cancer: challenge of the facts.
Wold J. Surg 27, 1057-1084, 2003

M. Kornmann, H. G. Beger, K. H. Link.
Chemosensivity testing and test-directed chrmotherapy in human pancreatic cancer.
Recent Results Cancer Res, 161, 180-195, 2003

B.U.M. Monz, H.-H. König, R. Leidl, L. Staib, K. H. Link.
Cost Effectiveness of Adding Folinic Acid to Flourouracil Plus Levamisole as Adjuvant. Chemotherapy in Patients with Colon Cancer in Germany
Pharmacoeconomics 21, 109-719, 2003

M. Kornmann, W. Schwabe, S. Sander, M. Kron, J. Sträter, S. Polat, E. Kettner, H. Weiser, W. Baumann, H. Schramm, P. Häusler, K. Otte, D. Beehnke, L. Staib, H. G. Beger, K-K. H. Link.
Thymidylate synthase and dihydropyrimidine dehydropenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Clinical Cancer Research, Vol 9, 4116-4124, 15.09.2003

M. Kornmann, H.G. Beger, K. H. Link.
Chemosensivity testing and test-directed chrmotherapy in human pancreatic cancer.
Recent Results Cancer Res, 161, 180-195, 2003

M. Kornmann, K. H. Link, I. Galuba, K. Ott, W. Schwabe, P. Häusler, P. Scholz, J. Sträter, S. Polat, Leibl, E. Kettner, Ch. Schlichting, W. Baumann, H. Schramm, U. Hecker, K. Ridwelski, J.H. Vogt, K.-U. Zerbian, F. Schütze, E.D. Kreuser, D. Behnke, H.G. Beger.
Association of Time to Recurrence with Thymidylate Synthase and Dihydropyrimidine Dehydrogenase mRNA Expression in Stage II and III Colorectal Cancer.
The Society for Surgery of the Alimentary Tract, 6,3, 331-337, 2002

M. Kornmann, H.G. Beger, K. H. Link.
Evaluation of toxicity using Oxaliplatin for regional intraarterial chemotherapy in patients with colrorectal liver metastases.
ICACT Abstract Book 11, S870, 2001

Leder, B. Prokopcyk, M. Ramadani, AJ. Cunningham, M Siech, A. Schwarz, B. Poch, K.H. Link, M. Bologna, S. Amin. D. Desai, D. Hoffmann, K. El-Bayoumy, H.G. Beger
Tobacco derived carcinogen in pancreatic juice of smokers – a causative factor for pancreatic cancer?
Langenbecks Archives of Surgery, 386, 380, 2001

Leder, B. Prokopcyk, M. Ramadani, AJ. Cunningham, M. Siech, A. Schwarz, B. Poch, K.H. Link, M. Bologna, S. Amin. D. Desai, D. Hoffmann, K. El-Bayoumy, H.G. Beger.
Detection of tobacco derived carcinogen in pancreatic juice of smokers – a role for the onset of pancreatic cancer?
Pancreas, 23, 448, 2001

Leder, A. Formentini, K. H. Link, TH. Mattfeld, H.G. Beger.
Successful reresections for pancreatic tumors .
Langenbeck´s Archives of Surgery, 236-388, 2001

JP Neoptolemos, DD Moffitt, JA Dunn, J. Almond, H.G. Beger, K. H. Link, P. Pederzoli, C. Bassi.
Survival, quality of life and quality-adjusted survival of patients in the ESPAC-1 trial: An European randomzied trial to assess the roles of adjuvant chemotherapy and chemoradiation in resectable pancreatic cancer.
Br. J. Surg 88/S1, 31, 2001

M. Kornmann, K. H. Link, S. Sander, M. Kron, J. Straeter, W. Schwabe, P. Haeusler, D. Behnke, H.G. Beger.
Thymidylate synthase and dihydropyrimidine dehydrogenase expression in stage II and III colorectal cancer patients receiving adjuvant 5-fluorouracil.
Eur. J. Cancer 37, S300, 2001

M. Kornmann, K. H. Link, W. Schwabe, P. Haeusler, J. Straeter, S. Polat, P Danenberg, D. Behnke, H.G. Beger.
MRNA quantitation of thymidylate synthase and dihydopyrimidine dehydrogenase can predict disease-free survival in stage IIb and III colon and stage II and III rectal cancer
Gastroenterology S870, 2001.

H.G Beger, M. Kornmann, K. H. Link
Chemosensitivity testing and test-directed chemotherapy in pancreatic cancer
Anti-Cancer Drugs 12, A13-A14, 2001

M. Kornmann, W. Schwabe, J Sträter, P. Häusler, H.G Beger, K. H. Link.
Intratumoral thymidylate synthase levels can predict disease free survival in patients with colorectal cancer receiving adjuvant 5-FU chemotherapy.
Deutsche Gesellschaft für Chirurgie Forumband 30, 113-115, 2001

P. Neoptolemos, J. A. Dunn, D. D. Stocken, J. Almond, K. H. Link, H. G. Beger, C. Bassi, M. Falconi, P. Pederzolli, C. Dervenis, L. Fernandesz-Cruz, F. Lacaine, A. Pap, D. Spooner, D. J. Kerr, Friess, M. W. Büchler for the members of the European Study Group on Pancreatic Cancer.
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.
The Lancet 358, 1576-1585, 2001

Ludger Staib, K. H. Link, H. G. Beger, and Members of the Forschungsgruppe Onkologie Gastrointestinaler Tumoren (FOGT).
Toxicity and Effects of Adjuvant Therapy in Colon Cancer: Results of the German Prospective, Controlled Randomized Multicenter Trial FOGT- 1.
Journal of Gastrointestinal Surgery, Vol.5, 275-281, 2001

M. Kornmann, W. Schwabe, J. Staeter, P. Haeusler, S. Polat, K. Danenberg, P. Danenberg, H.G. Beger, D. Behnke, K. H. Link.
Thymidylate synthase quantitation predicts for disease-free survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
American Association for Cancer Research, Annual Meeting, New Orleans, 24.-28.04.01,
Proc Am Assoc Cancer Res 42, 662, 2001

H.G Beger, M. Kornmann, K. H. Link.
Chemosensitivity testing and test-directed chemotherapy in pancreatic cancer.
Anti-Cancer Drugs 12, A13-A14, 2001

M. Kornmann, H.G. Beger, K. H. Link.
Evaluation of toxicity using Oxaliplatin for regional intraarterial chemotherapy in patients with colrorectal liver metastases.
ICACT Abstract Book 11, S870, 2001

Leder, A. Formentini, K. H. Link, TH. Mattfeld, H.G Beger.
Successful reresections for pancreatic tumors
Langenbeck´s Archives of Surgery, 236-388, 2001

JP Neoptolemos, DD Moffitt, JA Dunn, J. Almond, H.G. Beger, K. H. Link, P. Pederzoli, C. Bassi.
Survival, quality of life and quality-adjusted survival of patients in the ESPAC-1 trial: An European randomized trial to assess the roles of adjuvant chemotherapy and chemoradiation in resectable pancreatic cancer.
Br. J. Surg 88/S1, 31, 2001

J. Reusch, A. M. Keck, K. H. Link, H.H, Mohr.
Koexistenz von zwei unterschiedlichen neuroendokrinen Tumoren des oberen Gastrointestinaltraktes und des Pankreas.
Deutsche Medizinische Wochenschrift 123 (1998) 1472-1477

R. Mayer-Steinacker, Ch. Eggl, K. H. Link.
Telefonische Beratungsstelle und Interdisziplinäres Onkologisches Konsil des Tumorzentrums Ulm – Wege zur Therapieoptimierung und Kostensenkung. Bericht über das 16. Jahrestreffen des Baden-Württembergischen Tumorzentrums, Onkologischen Schwerpunkte, Onkologischen Arbeitskreise und verwandten Organisationen (ATO), Ludwigsburg, 14.-15.11.1997
Herausgeber: Krebsverband Baden-Württemberg e.V. (erschienen 1998)

J.P.Neoptolemos, D.J. Kerr, H.G. Beger, K. H. Link, P. Pederzoli, C. Bassi, C. Dervenis, L. Fernandez-Cruz, F. Lacaine, H. Friess, M. Büchler.
ESPAC-1 Trial Progress Report: The European Randomized Adjuvant Study Comparing Radiochemotherapy, 6 Months Chemotherapy and Combination Therapy versus Observation in Pancreatic Cancer.
Digestion 58 (1997) 570-577

M.M. Kornmann, K. H. Link, H-J. Lenz, J. Pillasch, R. Metzger, U. Butzer, et al..
Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy.
Cancer Letters 118 (1997) 29-35

H.G.Beger, M.H. Schoenberg, K. H. Link, F. Safi, D. Berger.
Die duodenumerhaltende Pankreaskopfresektion – Ein Standardverfahren bei chronischer Pankreatitis.
Chirurg 68 (1997) 874-880

F.Gansauge, K. H. Link, H.G. Beger.
Adjuvante Therapie des Pankreaskarzinoms.
Chir. Gastroenterol. 13 (1997) 90-94

J.Goerich, N. Rilinger, K. H. Link, R. Sokiranski, T. Fleiter, V. Kunze, M. Siech, A. Reiber, U. Leibing, M. Wikstroem, H. G. Beger, H.J. Brambs.
Angiographic alteration of the hepatic arteries following transcatheter arterial liver embolization.
Regional Cancer Treatment 9 (1996-1998) 208-216

J.Görich, N. Rilinger, R. Sokiranski, S. Krämer. K. H. Link, H.G. Beger, H-J Brambs.
Embolization of liver neoplams in patients with occluded celiac trunk.
Reg Cancer Treat 9 (1996) 79-82

F.Gansauge, S. Gansauge, N. Parker, M.I. Beger, B. Poch, K. H. Link, F. Safi, H. G. Beger.
CAM 17.1 – A new diagnostic marker in pancreatic cancer.
Br. J. Cancer 74 (1996) 1997-2002

F.Gansauge, K. H. Link, N. Rilinger, R. Kunz, H.G. Beger.
Adjuvante regionale Chemotherapie beim resezierten fortgeschrittenen Pankreascarcinom.
Chirurg 67 (1996) 362-365

F.Gansauge, S. Gansauge, Zobywalski A, Scharnweber C, K. H. Link, Nüssler A.K., H.G. Beger.
Differential Expression of CD44 Splice Variants in Human Pancreatic Adenocarcinoma and in normal Pancreas.
Cancer Res. 55 (1995) 5499-5503

F.Gansauge, K. H. Link, N. Rilinger, R. Kunz, H.G. Beger.
Regionale Chemotherapie beim fortgeschrittenen Pankreaskarzinom.
Med.Klin. 90 (1995) 501-505

J.Pillasch, K. H. Link, J. Görich, N. Rilinger, U. Widmaier, M. Weindel, H.J. Brambs, H.G. Beger.
Intraarterial chemotherapy for nonresectable liver cancer: Effectivity and toxicity of hepatic interaarterial infusion, chemoembolization and the combination modality.
Reg. Cancer Treat. 8 (1995) 160-165

R.Kunz, K. H. Link.
Laparoskopische Leistenhernienreparation: Transperitoneal oder extraperitoneal?
Chir. Gastroenterol. 111 (1995) 274-277

F.Porzsolt, A. Wirth, R. Mayer-Steinacker, W. Voigt, B. Heymer, K. H. Link, Schulte, E.M. Röttinger.
Qualitätssicherung in der Onkologie.
Münch Med Wschr 136 (1994) 371-376

P.Suhr, K. H. Link.
Strahlentherapie beim Rektumkarzinom.
Münch Med Wschr 136 (1994) 189-191

H.G. Beger, F.W. Eigler, R. Engelhardt, G. Hartung, Ch. Herfarth, P. Hermanek, Herrmann, D.K. Hossfeld, Th. Junginger, R. Kirchner, E. Kreuser, U. Laffer, K. H. Link, H.J. Meyer, H. Pichlmaier, W. Queisser, H.R. Raab, R. Sauer, Scheibe, H.J. Schmoll, W. Stock, H. Wilke.
Konsensus der CAO, AIO und ARO zur adjuvanten Therapie bei Kolon- und Rektumkarzinom vom 11.3.1994.
Onkologie 17 (1994) 291-293

Porzsolt, A. Wirth, R. Mayer-Steinacker, P. Suhr, N. Warszawski, M. Schulte, Negri, L. Kleeberger, K. H. Link, E. Betz, M.R. Sarkar, E. Röttinger.
Quality Assurance in Oncology: Definition of Treatment Goal and Assessment of Its Achievement.
Onkologie 17 (1994) 454-457

F. Gansauge, K. H. Link, N. Rilinger, H.G. Beger.
Regional chemotherapy in unresectable pancreatic cancer.
Pancreas 9 (1994) 788

F. Gansauge, K. H. Link, B. Poch, M.H. Schoenberg, H.G. Beger.
Detectable levels of autoantibodies directed against p53 in patients with pancreatic cancer.
Eur.J.Surg.Oncol. 20 (1994) 314

F. Safi, K. H. Link, H. G. Beger.
Is follow-up of colorectal cancer patients worthwile?.
Dis. Colon Rectum 36 (1993) 636-644

J. M. Friedrich, P. Schnarkowski, K. H. Link, K.A. Schumacher, S. Hoch.
Flushable stent-system for internal drainage in occlusive jaundice.
European Journal of Radiology 15 (1992) 45-48

L. Staib, K. H. Link, M. Büchler.
Steigerung der Zytotoxizität spezifischer monoklonaler Antikörper gegen humane Carzinomzellen durch GM-CSF in vitro.
Onkologie 14 (1991) 261-265

K. R. Aigner, H. Müller, H. Walther, K. H. Link.
Drug filtration in high dose regional chemotherapy.
Contributions to Oncology 29 (1988) 261-280

K. R. Aigner, H. Walther, K. H. Link.
Isolated liver perfusion with MMC/5-FU. Surgical technique, pharmacokinetics, clinical results.
Contributions to Oncology 29 (1988) 261-280

Schwemmle, K. H. Link, B. Rieck.
Rationale and indications for perfusion in liver tumors: Current data.
Worl J Surg 11 (1987) 534-40

Walther, K.R. Aigner, K. H. Link, H.J. Helling, K. Schwemmle.
Reduktion des postoperativen Ödems nach der isolierten hyperthermen Extremitätenperfusion durch prophylaktische Anwendung von Aprotinin.
Arzneimittelforschung/Drug Research 35 (1985) 1065-1069

K. R. Aigner, H.J. Helling, K. H. Link, H. Walther, G. Bil.
Zytostatikafiltration unter regionaler Chemotherapie.
Beitr. Onkol. 21 (1985) 229-245

K. R. Aigner, H. Walther, H.J. Helling, K. H. Link.
Die isolierte  Leberperfusion.
Beitr. Onkol. 21 (1985) 43-83

K. R. Aigner, K. H. Link, H.J. Helling, S. Stemmler.
Intraarterielle Infusion, experimentelle Grundlagen – Klinik.
Beitr. Onkol. 21 (1985) 84-107

K. R. Aigner, K. H. Link, H. Walther.
Hochdosierte regionale Chemotherapie bei Lebermetastasen.
Beitr. Onkol. 21 (1985) 90-98

K. R. Aigner, H. Walther, J.C. Tonn, K. H. Link, P. Schoch, K. Schwemmle.
Die isolierte Leberperfusion bei fortgeschrittenen Metastasen kolorektaler Karzinome.
Onkologie 7 (1984) 13-21

K. R. Aigner, K. H. Link, K. Schwemmle.
Die intermittierende arterielle Kurzinfusion zur lokalen Chemotherapie von Tumoren und
Metastasen der Leber.
Chirurg 55 (1984) 494-498

K. R. Aigner, K. H. Link, H. Walther.
Isolated hepatic perfusion in advanced hepatic metastases from colorectal primary.
Surgical Rounds 6 (1984) 92-104

K. R. Aigner, A. Jungbluth, K. H. Link, H. Walther, H. Müller, K. Schwemmle, Th. Ringenberg, G. Börger, R. Ruppel, L. Illig, H. Voigt.
Die isolierte hypertherme Extremitätenperfusion mit Vindesin, Dacarbazin und Cis-Platin bei der Behandlung Maligner Melanome.
Onkologie 6 (1984) 348-353

K. R. Aigner, K. H. Link, H. Woescher, W. Johannes, M. Hundeiker.
Regional perfusion of VX 2 carcinoma with cis-DDP.
Anticancer Research 3 (1983) 431-434

K. R .Aigner, H. Walther, K. H. Link, K.H. Muhrer, R. D. Filler, K. Schwemmle,
Seuffer, P. Schoch, C. Petreje, J.C. Tonn, H. Müller.
Die intraarterielle Zytostatikainfusion bei Lebertumoren.
Med.Klin. 78 (1983) 774-778

K. H. Muhrer, K. H. Link.
KCl carcinoma extracts as tumor antigens in the Electrophoretic Mobility Test: Clinical evaluation.
Cancer Detection and Prevention 6 (1983) 101-106

Kubota, E.B. Gehly, K. H. Link, Ch Heidelberger.
Development of two cloned epithelial cell lines from normal adult mouse and rat ventral prostates.
In Vitro 17 (1981) 965-978